Cargando…
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126715/ https://www.ncbi.nlm.nih.gov/pubmed/34012925 http://dx.doi.org/10.3389/fonc.2021.672612 |
_version_ | 1783693820833038336 |
---|---|
author | Xie, Mingying Xu, Xiaoling Fan, Yun |
author_facet | Xie, Mingying Xu, Xiaoling Fan, Yun |
author_sort | Xie, Mingying |
collection | PubMed |
description | Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in NSCLC, are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted drugs. The latest published clinical trial data on new small-molecule KRAS G12C inhibitors, AMG510 and MRTX849, indicate that these molecules may potentially help treat KRAS-mutant NSCLC. Simultaneously, within the immuno-therapeutic process, immune efficacy has been observed in those patients who have KRAS mutations. In this article, the pathogenesis, treatment status, progress of immunotherapy, and targeted therapy of KRAS-mutant NSCLC are reviewed. |
format | Online Article Text |
id | pubmed-8126715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81267152021-05-18 KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup Xie, Mingying Xu, Xiaoling Fan, Yun Front Oncol Oncology Lung cancer, the leading cause of cancer-related deaths worldwide, can be classified into small cell lung cancer and non-small cell lung cancer (NSCLC). NSCLC is the most common histological type, accounting for 85% of all lung cancers. Kirsten rat sarcoma viral oncogene (KRAS) mutations, common in NSCLC, are associated with poor prognosis, likely due to poor responses to most systemic therapies and lack of targeted drugs. The latest published clinical trial data on new small-molecule KRAS G12C inhibitors, AMG510 and MRTX849, indicate that these molecules may potentially help treat KRAS-mutant NSCLC. Simultaneously, within the immuno-therapeutic process, immune efficacy has been observed in those patients who have KRAS mutations. In this article, the pathogenesis, treatment status, progress of immunotherapy, and targeted therapy of KRAS-mutant NSCLC are reviewed. Frontiers Media S.A. 2021-05-03 /pmc/articles/PMC8126715/ /pubmed/34012925 http://dx.doi.org/10.3389/fonc.2021.672612 Text en Copyright © 2021 Xie, Xu and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xie, Mingying Xu, Xiaoling Fan, Yun KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title | KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title_full | KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title_fullStr | KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title_full_unstemmed | KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title_short | KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup |
title_sort | kras-mutant non-small cell lung cancer: an emerging promisingly treatable subgroup |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126715/ https://www.ncbi.nlm.nih.gov/pubmed/34012925 http://dx.doi.org/10.3389/fonc.2021.672612 |
work_keys_str_mv | AT xiemingying krasmutantnonsmallcelllungcanceranemergingpromisinglytreatablesubgroup AT xuxiaoling krasmutantnonsmallcelllungcanceranemergingpromisinglytreatablesubgroup AT fanyun krasmutantnonsmallcelllungcanceranemergingpromisinglytreatablesubgroup |